

# Journal of Materials Chemistry B

Materials for biology and medicine

[rsc.li/materials-b](https://rsc.li/materials-b)



Themed issue: Emerging Investigators 2020

ISSN 2050-750X



**PAPER**

Chelsea M. Magin *et al.*  
Clickable decellularized extracellular matrix as a new tool  
for building hybrid-hydrogels to model chronic fibrotic  
diseases *in vitro*

**Indexed in  
Medline!**

Cite this: *J. Mater. Chem. B*, 2020,  
8, 6814

## Clickable decellularized extracellular matrix as a new tool for building hybrid-hydrogels to model chronic fibrotic diseases *in vitro*†

Cassandra L. Petrou,<sup>ab</sup> Tyler J. D'Ovidio,<sup>b</sup> Deniz A. Bölükbas,<sup>cd</sup> Sinem Tas,<sup>cd</sup>  
R. Dale Brown,<sup>e</sup> Ayed Allawzi,<sup>e</sup> Sandra Lindstedt,<sup>dfg</sup> Eva Nozik-Grayck,<sup>e</sup>  
Kurt R. Stenmark,<sup>e</sup> Darcy E. Wagner<sup>ibcd</sup> and Chelsea M. Magin<sup>ib\*ab</sup>

Fibrotic disorders account for over one third of mortalities worldwide. Despite great efforts to study the cellular and molecular processes underlying fibrosis, there are currently few effective therapies. Dual-stage polymerization reactions are an innovative tool for recreating heterogeneous increases in extracellular matrix (ECM) modulus, a hallmark of fibrotic diseases *in vivo*. Here, we present a clickable decellularized ECM (dECM) crosslinker incorporated into a dynamically responsive poly(ethylene glycol)- $\alpha$ -methacrylate (PEG $\alpha$ MA) hybrid-hydrogel to recreate ECM remodeling *in vitro*. An off-stoichiometry thiol-ene Michael addition between PEG $\alpha$ MA (8-arm, 10 kg mol<sup>-1</sup>) and the clickable dECM resulted in hydrogels with an elastic modulus of  $E = 3.6 \pm 0.24$  kPa, approximating healthy lung tissue (1–5 kPa). Next, residual  $\alpha$ MA groups were reacted *via* a photo-initiated homopolymerization to increase modulus values to fibrotic levels ( $E = 13.4 \pm 0.82$  kPa) *in situ*. Hydrogels with increased elastic moduli, mimicking fibrotic ECM, induced a significant increase in the expression of myofibroblast transgenes. The proportion of primary fibroblasts from dual-reporter mouse lungs expressing collagen 1a1 and alpha-smooth muscle actin increased by approximately 60% when cultured on stiff and dynamically stiffened hybrid-hydrogels compared to soft. Likewise, fibroblasts expressed significantly increased levels of the collagen 1a1 transgene on stiff regions of spatially patterned hybrid-hydrogels compared to the soft areas. Collectively, these results indicate that hybrid-hydrogels are a new tool that can be implemented to spatiotemporally induce a phenotypic transition in primary murine fibroblasts *in vitro*.

Received 5th March 2020,  
Accepted 15th April 2020

DOI: 10.1039/d0tb00613k

rsc.li/materials-b

## 1. Introduction

Pathologic tissue remodeling is a hallmark of chronic fibrotic diseases.<sup>1–4</sup> It is characterized by persistent and excessive production of biochemically abnormal extracellular matrix (ECM), resulting in spatially heterogeneous increases in tissue stiffness.<sup>5–8</sup> Emerging evidence indicates that cell–matrix interactions drive the

progression of fibrosis, yet it is not clear whether changes in ECM composition, or the subsequent alterations in mechanical properties of the tissues, are the more potent driver of fibrosis.<sup>9–16</sup> Recently, Parker *et al.* proposed a model of pulmonary fibrosis in which an initial insult creates a lesion in the lung that is repaired with abnormal ECM. It is suggested that this pathologic ECM locally corrupts nearby fibroblasts, further remodeling the surrounding area and hence spreading fibrosis.<sup>11</sup> Herrera *et al.* suggest that these findings reveal mechanisms of fibrotic progression that can be self-perpetuating.<sup>14</sup> Thus, using pulmonary fibrosis as an archetype of chronic fibrotic disease, we present a novel hybrid-hydrogel that allows us to decouple fibrotic tissue composition from subsequent changes in mechanical properties to study the dynamic biological processes occurring in fibrosis.

Fibroblasts are a heterogeneous and versatile cell population with remarkable plasticity.<sup>17</sup> In healthy tissues these cells can differentiate into activated myofibroblasts marked by expression of Collagen 1a1 (Col 1a1) and alpha-smooth muscle actin ( $\alpha$ SMA) to promote wound healing. After healing, the

<sup>a</sup> Department of Bioengineering, University of Colorado, Anschutz Medical Campus, 12700 E 19th Ave MS C272 Aurora, Denver, CO 80045, USA

<sup>b</sup> Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12700 E 19th Ave MS C272 Aurora, Denver, CO 80045, USA. E-mail: chelsea.magin@cuanschutz.edu

<sup>c</sup> Department of Experimental Medical Sciences, Lund Stem Cell Center, and Wallenberg Molecular Medicine Center, Lund University, Sweden

<sup>d</sup> Wallenberg Center for Molecular Medicine, Lund University, Sweden

<sup>e</sup> Department of Pediatrics and Medicine, Cardiovascular Pulmonary Research Laboratory, University of Colorado, Anschutz Medical Campus, USA

<sup>f</sup> Cardiothoracic Surgery and Transplantation, Lund University Hospital, Sweden

<sup>g</sup> Department of Clinical Sciences, Lund University, Sweden

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0tb00613k

majority of these activated cells undergo apoptosis to restore homeostasis.<sup>18</sup> *In vitro* studies of myofibroblast activation in response to modulus changes in biomaterials have revealed that this differentiation is reversible.<sup>19–21</sup> However, a subpopulation of persistently activated, apoptosis-resistant fibroblasts have been identified in fibrotic tissues.<sup>22,23</sup> Currently the mechanisms underlying this progression, and the potential to reverse the persistently activated phenotype by therapeutic treatment, remain largely undefined.

Advances in lung decellularization techniques have fueled a growing interest in building biomaterials from decellularized ECM (dECM).<sup>24–26</sup> Hilster *et al.*, for example, reported a protocol for fabricating hydrogels using dECM derived from control and fibrotic human lungs. While these materials comprise the complex biochemical cues that cells encounter *in vivo*,<sup>27</sup> they are limited by poor mechanical properties that do not fully recapitulate diseased lung tissue. The elastic modulus of human lung tissue ranges from 1 to 5 kPa (healthy) to greater than 10 kPa (fibrotic).<sup>28,29</sup> Hydrogels comprised of dECM from healthy and fibrotic tissues demonstrated a similar trend, 1.5 kPa and 6.8 kPa, respectively, but ultimately could not match the increased stiffness of fibrotic lung.<sup>29</sup> To overcome this limitation, Sava *et al.* coated polyacrylamide-based hydrogels of modulus values ranging from 1.8 kPa to 23.7 kPa with healthy and fibrotic human-lung dECM. The results of these studies demonstrated that changes in  $\alpha$ SMA expression and organization were mechanosensitive regardless of composition.<sup>30</sup> Although this approach enabled researchers to decouple dECM composition from mechanical properties, the coating procedure limited experiments to 2D.<sup>30</sup> In another study, dECM was methacrylated and covalently crosslinked with gelatin methacrylamide to form 3D hydrogels from two naturally derived polymers with elastic modulus values ranging from approximately 12 kPa to 66 kPa.<sup>31</sup> While these experiments were certainly a breakthrough in modeling fibrotic disease *in vitro*, these static systems do not reproduce the spatiotemporal microenvironmental changes that occur during fibrotic disease progression and have been implicated as a major driver of cellular activation and disease progression.<sup>11,15,16,32,33</sup>

Dual-stage polymerization systems are one innovative way to recreate heterogeneous and localized ECM stiffening *in vitro*.<sup>34–37</sup> These dual-stage polymerization systems often include a “click” reaction that proceeds under mild conditions and is highly reactive in a fast, specific, and efficient manner.<sup>38</sup> The specificity of click crosslinking allows the user to exploit sequential reactions to control hydrogel mechanical properties. Dynamic responsiveness has been initiated in a variety of hydrogels by user-controlled mechanisms, such as light, to probe how cells interact with and receive information from the extracellular microenvironment.<sup>39</sup> While these systems are capable of recapitulating the spatiotemporal heterogeneity of the biophysical changes that occur in the ECM during disease progression, two key limitations remain: (1) these biomaterials do not recapitulate the dynamic alterations in ECM composition that characterize fibrotic disease, and (2) existing material systems that mimic the water content of tissues are susceptible

to hydrolysis over the long culture periods required to emulate chronic disease.


Here, we present a strategy for synthesizing clickable dECM and combining it with a hydrolytically stable, phototunable poly(ethylene glycol) (PEG) backbone in a dual-stage polymerization system that allows us to decouple fibrotic tissue composition from subsequent changes in mechanical properties to dynamically study the biological processes occurring in fibrosis. The novel hybrid-hydrogel system provides predictable control of initial matrix mechanical properties over a large range of moduli ( $E = 3.63 \pm 0.24$  to  $13.35 \pm 0.83$  kPa) and facilitates spatiotemporal control over precise increases in elastic modulus *in situ*. Primary platelet-derived growth factor receptor alpha-positive (PDGFR $\alpha$ +) fibroblasts from the alveolar niche<sup>40</sup> were isolated from adult dual-transgenic reporter mice. These mice express green or red fluorescent protein in response to Col1a1 or  $\alpha$ SMA or transgene expression,<sup>41</sup> respectively, and are used to monitor cellular responses to this new biomaterial. PDGFR $\alpha$  fibroblasts from the alveolar niche were selected for these assays because this is the proposed site of initial injury and remodeling in pulmonary fibrosis.<sup>42–44</sup> Fibroblast activation was characterized by measuring expression of these transgenes in response to initial substrate moduli, dynamic stiffening ranging from healthy ( $E = 1–5$  kPa) to diseased levels ( $E > 10$  kPa), and patterns of alternating soft and stiff areas to mimic the effect of heterogeneous mechanical properties observed in fibrosis.<sup>45</sup> We demonstrate the utility of this hybrid-hydrogel system for dynamically probing cell–matrix interactions with spatial control, highlighting a new approach for understanding the biochemical and biophysical contributions to fibrotic disease progression.

## 2. Materials and methods

### 2.1. Small molecule and macromer synthesis

**Synthesis of lithium phenyl-2,4,6-trimethylbenzoylphosphinate.** Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) photo-initiator was synthesized and characterized as previously described.<sup>46,47</sup>

**Synthesis of ethyl 2-(bromomethyl) acrylate.** Ethyl 2-(bromomethyl)acrylate (EBrMA) was synthesized following a previously published protocol.<sup>48</sup> Briefly, 60 mmol ethyl 2-(hydroxymethyl) acrylate (EHMA; Sigma) was dissolved in 60 mL diethyl ether in a round-bottom flask and 21 mmol phosphorous tribromide (PBr<sub>3</sub>; Acros Organics) was slowly added while cooling the reaction vessel with an ice bath. Then, the mixture was warmed to room temperature and stirred for 3 h to complete the reaction. Water (5 mL) was added to the mixture and it was extracted with hexane (Sigma) three times. The organic solutions from all three extractions were combined, washed with brine, and dried with anhydrous magnesium sulfate (MgSO<sub>4</sub>; Fisher Scientific). The solvent was removed by rotary evaporation at 60 °C to give the final product at a 90% yield. The functionalization of the product was verified by <sup>1</sup>H NMR performed on a Bruker Advance-III 300 NMR Spectrometer (7.05 T) (Fig. S1, ESI†). <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  (ppm)



**Fig. 1** (A) Schematic depicting the lung decellularization process. Briefly, native lungs were sequentially perfused with Triton X-100, sodium deoxycholate (SDC) solution, DNase solution, and peracetic acid to remove all cellular components before being mechanically digested and lyophilized to form a powder. (B) Decellularized porcine ECM was treated with Traut's reagent at a 75-molar excess to primary amines ( $\text{NH}_2$ ) and 2 mM EDTA to convert free primary amines to thiols creating a clickable dECM crosslinker. (C) A significant increase in thiol concentration was measured post-treatment using an Ellman's assay ( $n = 6$ ,  $**p < 0.0001$ , ANOVA, Tukey test). (D) Silver-stained SDS-PAGE results showed a loss of high molecular weight proteins ( $\geq 250$  kDa) and an increase in proteins below 15 kDa following thiolation, indicating that the treatment likely cleaved a portion of the dECM proteins into clickable dECM peptides.

1.3 (t, 3H,  $-\text{CH}_3$ ), 4.16 (s, 2H,  $-\text{CH}_2-\text{Br}$ ), 4.25 (q, 2H,  $-\text{CH}_2-\text{O}-$ ), 5.9 and 6.3 (s, 1H,  $=\text{CH}_2$ ).

**Synthesis of poly(ethylene glycol)-alpha methacrylate.** Poly(ethylene glycol)-hydroxyl (PEG-OH; 8-arm,  $10\text{ kg mol}^{-1}$ ; JenKem Technology) was dissolved in anhydrous tetrahydrofuran (THF; Sigma) in a round-bottom flask and purged with argon. Sodium hydride (NaH; Sigma) was injected through a septum into the reaction vessel at  $3\times$  molar excess to PEG-hydroxyl groups.<sup>48</sup> EBrMA was added drop-wise using an addition funnel at a  $6\times$  molar ratio to PEG-OH groups, and the reaction was stirred at room temperature for 72 h protected from light. The mixture was neutralized with 1 N acetic acid until gas evolution ceased and filtered through Celite 545. The solution was concentrated by rotary evaporation at  $60^\circ\text{C}$ , precipitated dropwise into ice-cold diethyl ether (Fisher Scientific) and washed three times in diethyl ether. The solid product was then dried under vacuum overnight at room temperature. The product was purified using dialysis ( $1\text{ kg mol}^{-1}$  MWCO, ThermoFisher) for four days, and then flash frozen in liquid nitrogen and lyophilized to give the final product. The functionalization of the product was verified by  $^1\text{H NMR}$  (Fig. S2, ESI $^\dagger$ ).  $^1\text{H NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  (ppm) 1.23 (t, 6H,  $\text{CH}_3$ -), 3.62 (s, 114H, PEG backbone), 4.17–4.21 (t, s, 8H,  $-\text{CH}_2-\text{C}(\text{O})-\text{O}-\text{O}$ ,  $-\text{O}-\text{CH}_2-\text{C}(\text{=CH}_2)-$ ), 5.90 (s, 1H,  $-\text{C}=\text{CH}_2$ ), 6.31 (s, 1H,  $-\text{C}=\text{CH}_2$ ).

**Synthesis of poly(ethylene glycol)-methacrylate.** Poly(ethylene glycol)-methacrylate (PEGMA) was synthesized by adapting a

previously published protocol<sup>49,50</sup> (detailed in the ESI $^\dagger$ ) and characterized using  $^1\text{H NMR}$  (Fig. S3, ESI $^\dagger$ ).

## 2.2. dECM derivation and thiolation

**Porcine lung decellularization.** ECM was derived by decellularizing porcine lung tissue as previously described.<sup>51</sup> Briefly, the heart–lung block was removed from the thoracic cavity and sequentially perfused through the trachea/main bronchus and pulmonary artery/main vessel with a perfusion pump at  $1\text{--}3\text{ L min}^{-1}$  with a DI water solution containing  $5\times$  penicillin/streptomycin (PS). Next, the lungs were perfused with 0.1% Triton X-100 solution and incubated overnight at  $4^\circ\text{C}$  under agitation, followed by subsequent washing with DI water solution. The lungs were then perfused with 2% sodium deoxycholate and again incubated overnight at  $4^\circ\text{C}$  under agitation, followed by perfusion with DI water solution. Next, lungs were perfused with the following solutions and incubated at room temperature for 1 h each followed by DI water solution: 1 M sodium chloride,  $30\text{ }\mu\text{g mL}^{-1}$  DNase, and 0.1% peracetic acid in 4% ethanol to remove all cellular components (Fig. 1a). Finally, the tissue was mechanically minced and treated again with DNase solution at  $4^\circ\text{C}$  overnight, washed *via* centrifugation with ultrapure water, and lyophilized to form a powder.<sup>52</sup> Sufficient decellularization was confirmed through quantification of dsDNA by Quant-iT $^\text{TM}$  PicoGreen $^\text{TM}$  dsDNA Assay Kit (ThermoFisher), analysis of residual DNA fragments by gel electrophoresis,

and hematoxylin and eosin staining of the decellularized lung tissue (Fig. S4, ESI†).<sup>52</sup>

**dECM thiolation.** To create a clickable, decellularized ECM (dECM) crosslinker, the free primary amines on the dECM were converted into thiol moieties using 2-iminothiolane hydrochloride (Traut's reagent; Sigma) (Fig. 1b).<sup>53</sup> The primary amine concentration was measured using a ninhydrin (NHN; Sigma) assay according to the manufacturer's protocol. Next, the dECM was reacted with a 75-molar excess Traut's reagent to primary amine concentration with 2 mM ethylenediaminetetraacetic acid (EDTA; ThermoFisher) for 2 h at room temperature. Following this reaction, the solution was filtered through Zeba Spin Desalting Columns ( $7 \text{ kg mol}^{-1}$  MWCO, 10 mL; ThermoFisher) to remove the Traut's reagent. The final solution was lyophilized and the number of thiol groups that were introduced to the dECM was quantified using Ellman's reagent (5,5'-dithio-bis-(2-nitrobenzoic acid) or DTNB; Sigma) according to manufacturer's protocol.

A Pierce™ Silver Stain Kit (ThermoFisher) was used to qualitatively analyze protein size distribution in dECM compared to thiolated-dECM. Lyophilized dECM and thiolated-dECM were lysed in RIPA buffer for 1 h on ice and loaded into sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. After resolving the protein by size, the gels were silver stained according to the manufacturer's protocol to visualize the size (*via* molecular weight) of dECM proteins, peptides, and fragments before and after thiolation.<sup>54</sup>

### 2.3. Hydrogel formation

The thiol-functionalized dECM (clickable dECM) and 1,4-dithiothreitol (DTT; Acros Organics) crosslinkers were reacted with PEG $\alpha$ MA in a base-catalyzed Michael addition reaction off-stoichiometry at a 3:8 thiol to  $\alpha$ MA ratio. The hydrogel formulation was optimized by varying the percentage of DTT to clickable dECM to achieve a desired elastic modulus. The clickable dECM was dissolved in 15 mM solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP; Fisher Scientific) for 1 h at a 20 $\times$  molar ratio to the thiol concentration as determined by the Ellman's assay. Stock solutions of PEG $\alpha$ MA ( $0.4 \text{ mg } \mu\text{L}^{-1}$ ), DTT (500 mM), and a peptide sequence that mimics adhesive ligands (0.2 mM; CGRGDS; GL Biochem) were prepared in 0.3 M, pH 8 4-(2-hydroxyethyl)-1piperazine-ethanesulfonic acid buffering agent (HEPES; Life Technologies). A precursor solution was prepared by combining the clickable dECM, DTT, CGRGDS, and then adding the PEG $\alpha$ MA. Hydrogels were polymerized by placing 40  $\mu\text{L}$  drops of the precursor solution between two hydrophobic glass slides treated with SigmaCote (Sigma). The reaction was allowed to proceed for 1 h at 37 °C. Hydrogels were equilibrated in PBS at 4 °C, with or without 2.2 mM LAP photo-initiator for 24 h. Hydrogels swollen in LAP were exposed to light (365 nm light,  $10 \text{ mW cm}^{-2}$ ) for 5 min using an OmniCure Series 2000 UV lamp (Lumen Dynamics) to create stiff hybrid-hydrogel samples. For cell experiments, the hydrogel-forming stock solutions were dissolved in sterile 0.3 M, pH 8 HEPES. The precursor solution was made from the resulting stocks under sterile conditions. Glass coverslips

(18 mm; Fisher Scientific) were silanated with (3-aminopropyl)-trimethoxysilane (Sigma) using a liquid deposition technique.<sup>55</sup> Hydrogel precursors were deposited in 90  $\mu\text{L}$  drops between hydrophobic glass slides and silanated cover slips for 1 h at 37 °C. Hydrogels were then swollen in complete medium (DMEM/F12; Gibco) supplemented with 100 U  $\text{mL}^{-1}$  penicillin, 100  $\mu\text{g mL}^{-1}$  streptomycin, 2.5  $\mu\text{g mL}^{-1}$  amphotericin B (Life Technologies), and 10% fetal bovine serum (FBS; ThermoFisher) for 24 h at 37 °C. The medium was formulated with or without 2.2 mM LAP for stiffening or use as soft hybrid-hydrogel samples in experiments, respectively.

### 2.4. Hybrid-Hydrogel characterization

Rheology was used to assess the mechanical properties of the hydrogels following gelation. Hydrogel samples (height = 300  $\mu\text{m}$ ; diameter = 8 mm) were loaded onto a Discovery HR2 rheometer (TA Instruments) with an 8 mm parallel plate geometry and the Peltier plate set at 37 °C. The geometry was lowered until the instrument read 0.03 N axial force and the gap distance was noted. The gap distance between the plate and the geometry was adjusted until the storage modulus measurement ( $G'$ ) plateaued and a percent compression of the specific hydrogel was defined and used thereafter.<sup>56</sup> The samples were subjected to frequency oscillatory strain with a frequency range of 0.1 to 100  $\text{rad s}^{-1}$  at 1% strain. The elastic modulus ( $E$ ) was calculated using rubber elastic theory, assuming a Poisson's ratio of 0.5 for bulk measurements of elastic hydrogel polymer networks.<sup>21</sup>

Hybrid-hydrogel morphology was visualized by scanning electron microscopy (SEM). Briefly, soft and stiffened hybrid-hydrogels were frozen in liquid nitrogen and then lyophilized at  $-80$  °C for 24 h (Freezone 4.5, Labconco, US). Samples were subsequently sputter-coated with 2 nm platinum/palladium (80/20) in a Quorum Q150T ES turbo pumped sputter coater and examined with the secondary electron detector at 1.5 kV in a Jeol JSM-7800F FEG-SEM.

Distribution of the clickable dECM and the PEG backbone components within hybrid-hydrogels was visualized *via* confocal microscopy. Clickable dECM crosslinker was treated with TCEP for 1 h as described above. AlexaFluor™ 647 C<sub>2</sub> Maleimide (ThermoFisher) at 0.8 mM was added to this solution and allowed to react for 2 h to conjugate the dye to the thiols on the crosslinker. Hybrid-hydrogels were polymerized by placing a 40  $\mu\text{L}$  drop of the precursor solution containing the labeled dECM crosslinker on a silanated glass slide and allowing the reaction to proceed for 1 h at 37 °C. The PEG component of these hybrid-hydrogel samples was visualized through immunostaining. Briefly, samples were blocked with 5% bovine serum albumin (BSA; ThermoFisher) for 1 h. Recombinant anti-PEG antibody produced in rabbit (ab170969; abcam) was diluted 1:10 in an immunofluorescence (IF) solution containing 3% v/v BSA with 0.1% v/v Tween 20 (Sigma) in PBS. Samples were incubated with the primary antibody solution overnight at 4 °C. After washing three times with IF solution, the hybrid-hydrogels were incubated with goat-anti-rabbit IgG Alexa Fluor-488 secondary antibody (1:200 in IF solution, ThermoFisher) overnight at 4 °C.

Samples were rinsed with PBS three times and imaged on a Zeiss LSM780 confocal microscope.

### 2.5. Hydrolytic stability

Hybrid-hydrogels and fully synthetic hydrogels (17 wt% poly(ethylene glycol)-methacrylate (PEGMA;  $10 \text{ kg mol}^{-1}$ ) cross-linked with 100% DTT) were fabricated, swollen in 2.2 mM LAP, stiffened by exposure to light ( $365 \text{ nm light}, 10 \text{ mW cm}^{-2}$ ) for 5 min (OmniCure Series 2000; Lumen Dynamics), and two assays were performed on each condition every 10 days for up to 60 days to examine the hydrolytic stability. Rheology was completed as described above on each sample before the sample was placed in DI water, lyophilized, and weighed to record the dry polymer mass.

### 2.6. Spatial patterning of hybrid-hydrogel modulus

Hydrogels were fabricated as described above for cell experiments and swollen in DMEM/F12 supplemented with  $100 \text{ U mL}^{-1}$  penicillin,  $100 \mu\text{g mL}^{-1}$  streptomycin,  $2.5 \mu\text{g mL}^{-1}$  amphotericin B, 1% FBS, 2 mM LAP, and  $10 \mu\text{M}$  methacryloxyethyl thiocarbonyl rhodamine B (Polysciences Inc.). Hybrid-hydrogels were exposed to  $365 \text{ nm light}$  at  $10 \text{ mW cm}^{-2}$  through a chrome-on-quartz photomask to spatially pattern defined regions of increased elastic modulus. Two line patterns were produced with either 50- or 100-micron width and spacing.

### 2.7. Primary cell isolation

All animal procedures were performed in an AAALAC-accredited facility in accordance with the Guide for the Care and Use of Laboratory Animals<sup>57</sup> and approved by the University of Colorado Denver Institutional Animal Care and Use Committee. Male and female, 8–12 week-old, dual-transgenic reporter C57BL/6J mice were bred for this study. Fibroblasts from this GFP-Col1a1  $\times$  RFP- $\alpha$ SMA strain express green fluorescent protein (GFP) or red fluorescent protein (RFP) transgenes upon the expression of Col1a1 and  $\alpha$ SMA promoters, respectively.<sup>41</sup> Wildtype littermates, C57BL/6J mice, 8–12 weeks old, (GFP–, RFP–) which resulted from the breeding protocol were used for cell viability experiments.

Cells isolated from enzymatically dispersed whole lung were sorted using magnetic microbeads conjugated with specific monoclonal antibodies to purify a PDGFR $\alpha$ -positive fibroblast population, as follows. At the time of animal sacrifice, the heart–lung block was collected. The lungs were filled with room temperature dispase solution ( $5 \text{ U mL}^{-1}$ ; Life Technologies) and allowed to collapse. Next, lungs were inflated through the trachea with 1% low melt melting point agarose (LMP Ultra-pure; Life Technologies) and placed in PBS on ice until the agarose solidified. The lungs were transferred to fresh dispase solution ( $5 \text{ U mL}^{-1}$ ) in a 50 mL conical tube and incubated for 45 min at room temperature. Then, the lungs were transferred to GentleMACS C tubes (Miltenyi Biotec, Inc.) containing 3 mL of digestion solution: complete DMEM with high glucose (Life Technologies) supplemented with  $100 \text{ U mL}^{-1}$  penicillin,  $100 \mu\text{g mL}^{-1}$  streptomycin,  $2.5 \mu\text{g mL}^{-1}$  amphotericin B, and 10% FBS with DNase solution ( $0.33 \text{ U mL}^{-1}$ ; Life Technologies).

The lungs were sequentially digested using a GentleMACS Dissociator (Miltenyi Biotec, Inc.) at 275 rpm for 37 seconds and 3300 rpm for 38 seconds. Digest solution was filtered using a  $40 \mu\text{m}$  cell strainer, centrifuged at 1500 rpm for 10 min to remove the supernatant, and the cells were resuspended in complete medium for counting.

After counting, cells were resuspended in a buffer consisting of 0.5% bovine serum albumin (BSA) and 2 mM EDTA in PBS (PEB buffer).  $10 \mu\text{L}$  of magnetic microbeads conjugated to monoclonal anti-mouse CD31 and to monoclonal anti-mouse CD45 antibodies (Miltenyi Biotec, Inc.) were added to the solution for every  $10^7$  cells counted to magnetically label the mature endothelial cells and leukocytes respectively. The solution was triturated twice to mix and incubated at  $4 \text{ }^\circ\text{C}$  for 15 min. The cells were then washed with PEB buffer, centrifuged, and resuspended in  $500 \mu\text{L}$  PEB buffer. Next, magnetically labeled cells in PEB buffer were applied to sorting columns (LS; Miltenyi Biotec, Inc.) and placed in the magnetic field of a Quadromacs Separator (Miltenyi Biotec, Inc.) and allowed to flow through at room temperature until the column reservoir was empty and the columns were rinsed with 9 mL of PEB buffer. Cells that passed through the columns in this step were the CD45–/CD31– fraction, and the CD45+/CD31+ cell fraction was discarded. The CD45–/CD31– fraction was counted, centrifuged to remove the supernatant, and resuspended in  $90 \mu\text{L}$  PEB buffer for every  $10^7$  cells counted.  $10 \mu\text{L}$  of magnetic microbeads conjugated to monoclonal anti-mouse CD140a antibodies (Miltenyi Biotec, Inc.) were added to the solution for every  $10^7$  cells counted to magnetically label PDGFR $\alpha$ + fibroblasts. The solution was triturated twice to mix and incubated at  $4 \text{ }^\circ\text{C}$  for 15 min. This cell suspension was loaded into a new sorting column, placed into the magnetic field, and rinsed to remove unlabeled cells. The column was removed from the magnetic separator and immediately flushed with 5 mL PEB buffer into a 50 mL conical tube for collection. This resulting solution contained the desired cell fraction (CD45–, CD31–, and CD140a+).<sup>58</sup>

### 2.8. Cellular viability

Sorted PDGFR $\alpha$ + fibroblasts from wildtype C57BL/6J mice, 8–12 weeks old, (GFP–, RFP–) were seeded onto soft and stiff hybrid-hydrogels ( $n = 6$ ) at a density of  $10\,000 \text{ cells per cm}^2$  and cultured in complete medium (DMEM/F12 supplemented with  $100 \text{ U mL}^{-1}$  penicillin,  $100 \mu\text{g mL}^{-1}$  streptomycin, and  $2.5 \mu\text{g mL}^{-1}$  amphotericin B and 10% FBS). Cell-seeded hydrogels were incubated with 10% v/v PrestoBlue™ Cell Viability Reagent (ThermoFisher) in culture medium for 3 h in a humidified incubator ( $37 \text{ }^\circ\text{C}$ , 5%  $\text{CO}_2$ ) on days 1, 3, 5, 7, and 9. Three aliquots of the media containing viability reagent were then transferred to a 96-well plate and read on a plate reader (540 nm excitation, 600 nm emission; Synergy H1 Hybrid Multi Mode Reader; BioTek). Average fluorescence intensity values for all conditions at each time point were normalized to the respective readings acquired on day 1 to calculate normalized metabolic activity.

Sorted PDGFR $\alpha$ + fibroblasts from wildtype C57BL/6J mice, 8–12 weeks old, (GFP–, RFP–) were seeded onto soft and stiff hydrogels at a cell density of  $10\,000 \text{ cells per cm}^2$  and separate

cell-seeded hydrogels were stained on days 1 and 7 with 1 mM calcein-AM (ThermoFisher) diluted 1:3000 in media to visualize live cells and  $2 \mu\text{g mL}^{-1}$  molecular probe Hoechst 33342, Trihydrochloride, Trihydrate (Tocris) to visualize cell nuclei and incubated for 30 min at  $37^\circ\text{C}$ . The cells were then rinsed with PBS and imaged. Sorted PDGFR $\alpha$ + fibroblasts from wild-type C57BL/6J mice, 8–12 weeks old, (GFP–, RFP–) were also seeded onto soft hydrogels for stiffening experiments. Photo-initiator (LAP) was added to the media on day 6. Hydrogels were stiffened on day 7 by exposure to light ( $365 \text{ nm}$  light,  $10 \text{ mW cm}^{-2}$ ) for 5 min and then stained and imaged on day 9 as described above. Cells stained by both calcein-AM and Hoechst were determined to be alive, while cells only stained by Hoechst were determined to be dead.<sup>59</sup>

### 2.9. Cellular activation

PDGFR $\alpha$ + fibroblasts from dual-reporter (GFP-Col1a1  $\times$  RFP- $\alpha$ SMA) mice (8–12 weeks old) were seeded onto soft or stiff hydrogels at a density of 10 000 cells per  $\text{cm}^2$  and cultured in medium (DMEM/F12 supplemented with 100 U  $\text{mL}^{-1}$  penicillin, 100  $\mu\text{ mL}^{-1}$  streptomycin, and  $2.5 \mu\text{g mL}^{-1}$  amphotericin B, and 1% FBS). Cells were intentionally seeded at a relatively low density to enable single cell analysis without cells reaching confluence.<sup>60</sup> All cell-seeded hydrogels were incubated in a humidified incubator ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ ). On day 6, the cell culture medium was replaced with complete medium containing 2.2 mM LAP photo-initiator on half of the soft hydrogels. The following day (day 7) soft and stiff hydrogels ( $n = 4$ ) were collected for analysis and the soft hydrogels treated with LAP ( $n = 4$ ) were stiffened by exposure to  $365 \text{ nm}$  light at  $10 \text{ mW cm}^{-2}$  for 5 min, rinsed three times to remove any residual LAP, and incubated ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ ) for two more days before being collected for analysis on day 9 (Fig. 5a). This process was repeated for a total of three biological replicates. All samples were rinsed with PBS, fixed with 4% v/v paraformaldehyde (Electron Microscopy Sciences) in PBS for 30 min at room temperature, and quenched with 100 mM glycine (Sigma) in PBS for 15 min at room temperature. Following fixation, cells were rinsed with PBS, permeabilized with 0.2% Triton X-100 for 10 min at room temperature, and then stained with DAPI (1:10 000, Sigma) for 15 min at room temperature. Finally, samples were washed with PBS and mounted using Prolong Gold Antifade reagent (ThermoFisher) to preserve for imaging.

### 2.10. Spatial control over cellular activation

Sorted PDGFR $\alpha$ + dual-reporter fibroblasts were seeded onto spatially patterned (*i.e.* stiffened) hydrogels ( $n = 6$ ) at a cell density of 15 000 cells per  $\text{cm}^2$  and cultured in medium supplemented with 1% FBS. Samples were incubated in a humidified incubator ( $37^\circ\text{C}$ , 5%  $\text{CO}_2$ ) for seven days, then collected and prepared for activation analysis as described above.

### 2.11. Fluorescence microscopy and image analysis

All microscopy was performed using an upright, epifluorescent microscope (BX-63, Olympus). Ten fields of view were randomly selected and imaged on each sample at  $10\times$  magnification. Image analysis for activation experiments was performed using

ImageJ software to count cells positive for GFP-Col1a1 and/or RFP- $\alpha$ SMA. These cell counts were divided by the total cell number acquired by counting DAPI-positive nuclei to calculate the proportion of GFP-Col1a1-positive and RFP- $\alpha$ SMA-positive cells on each sample.


### 2.12. Statistical analysis

All quantitative hydrogel characterization was performed with a minimum of  $n = 3$  technical replicates. All *in vitro* experimental studies involving cell culture for the evaluation of activation were performed with  $n = 4$  technical replicates with 3 biological replicates. Data were presented as mean  $\pm$  standard error of the mean (SEM) or 95% confidence interval as described in each figure caption. GraphPad Prism 8 Software was used to perform all statistical analyses. One-way analysis of variance (ANOVA) with Tukey's *post hoc* multiple comparisons tests was done on each experimental measure with multiple groups for pairwise comparisons among conditions with a 95% confidence interval. A 2-tailed Student's *t*-test was used when comparing fewer than three groups. *P*-Values of  $<0.05$  were considered significant and designated on plots as  $* < 0.05$  or  $** < 0.0001$ . Linear regression analysis with a 95% confidence interval was completed to compare trends over time.

## 3. Results and discussion

### 3.1. Hybrid-hydrogel characterization

We present a method for synthesizing a clickable dECM cross-linker that facilitates a dual-stage polymerization reaction providing dynamic control over matrix mechanical properties in real time that is hydrolytically stable and can be implemented in 3D. First, porcine lungs were decellularized<sup>52</sup> and mechanically digested into small fragments (Fig. 1a). Next, clickable dECM was generated by converting the naturally occurring primary amines on native dECM molecules to thiol moieties using Traut's reagent (Fig. 1b). The average primary amine concentration of porcine dECM was measured to be  $0.184 \pm 0.0135 \mu\text{mol mg}^{-1}$  by a Ninhydrin assay. The average thiol concentration, measured by Ellman's assay before treatment with Traut's reagent, was negligible ( $0.00753 \pm 0.0273 \mu\text{mol mg}^{-1}$ ). Following treatment with Traut's reagent, however, this thiol concentration increased significantly to  $0.189 \pm 0.0117 \mu\text{mol mg}^{-1}$ , indicating successful addition of thiols to dECM ( $P < 0.05$ , Tukey Test) (Fig. 1c). Traut's reagent has been used extensively to thiolate natural polymers and growth factors,<sup>61</sup> but the impact of this reaction on dECM is not yet well understood. Therefore, we sought to investigate whether the thiolation process induced degradation of dECM molecules. As many conventional protein measurement techniques rely on the detection of amines, we performed silver staining of dECM pre and post-thiolation on SDS-PAGE gels. Silver staining is a commonly used protein detection technique with high sensitivity that relies on the binding of silver ions to the negative side chains of proteins<sup>54</sup> and thus avoids potential interference due to thiolation of amine groups. Silver staining of dECM before thiolation revealed a wide distribution of proteins from  $> 15 \text{ kDa}$



**Fig. 2** (A) Schematic of the dual-stage polymerization reaction that combined PEG $\alpha$ MA and the clickable dECM crosslinker with DTT and CGRGDS to enable spatiotemporal control over stiffening. (B) The elastic modulus of soft and stiffened hybrid hydrogels decreased with increasing dECM content ranging from 14 mol% to 25 mol% dECM ( $n = 4$ , mean  $\pm$  SEM). (C) Hybrid hydrogel formulations were adjusted so that soft and stiffened samples resulted in elastic modulus values within healthy and pathologic ranges, respectively ( $n = 4$ , mean  $\pm$  SEM,  $*p < 0.05$ , ANOVA, Tukey test). (D) Scanning electron micrographs of soft and stiffened hybrid hydrogels. Scale bars, 25  $\mu$ m. (E) Representative confocal images of hybrid hydrogels stained for PEG $\alpha$ MA (green) and dECM (red) show uniform mixing of the two components throughout the samples. Scale bars, 50  $\mu$ m.

to some above 250 kDa. In contrast, a loss of high molecular weight proteins ( $\geq 250$  kDa) and an increase in proteins  $< 15$  kDa was observed following thiolation, indicating that the treatment likely cleaved a portion of the dECM proteins into clickable dECM peptides (Fig. 1d).


To demonstrate the utility of this clickable dECM crosslinker, it was incorporated into a PEG $\alpha$ MA-based stiffening hybrid-hydrogel system. First, clickable dECM was reacted off-stoichiometry with DTT and a peptide sequence mimicking a binding region on the basement membrane protein fibronectin (CGRGDS) through a thiol-ene Michael addition reaction. This thiol-ene polymerization was preceded by a “click” orthogonal step-growth mechanism where one thiol of the clickable dECM, DTT, or CGRGDS, reacted with one  $\alpha$ MA, leading to a homogeneous distribution in crosslinks.<sup>39</sup> The hybrid-hydrogel was then dynamically stiffened by sequentially reacting the residual  $\alpha$ MA moieties in the presence of LAP photoinitiator *via* a

light-initiated homopolymerization (Fig. 2a). Rheological measurements were performed to quantify the shear elastic modulus ( $G'$ ) of hybrid-hydrogels containing various amounts of clickable dECM and converted to elastic modulus ( $E'$ ) using rubber elasticity theory assuming a Poisson's ratio of 0.5 for bulk measurements of elastic hydrogel polymer networks.<sup>21</sup> This assumption has been used extensively to determine the bulk modulus of PEG-based hydrogels<sup>19,62,63</sup> and has been previously confirmed using atomic force microscopy.<sup>64</sup> The elastic modulus scaled directly with total molar percent of clickable dECM as expected (Fig. 2b). The final formulation for the hybrid-hydrogels consisted of 15 wt% PEG $\alpha$ MA and a molar thiol ratio of 75% DTT to 25% clickable dECM with 1 mM CGRGDS pendant peptide. The soft hybrid-hydrogel exhibited an elastic modulus of  $3.63 \pm 0.24$  kPa within the range of healthy lung tissue (1 to 5 kPa)<sup>28,65</sup> (Fig. 2c). Following sequential crosslinking, stiff hybrid-hydrogels were dynamically stiffened to an elastic modulus of  $13.35 \pm 0.83$  kPa, replicating fibrotic stiffness ( $> 10$  kPa)<sup>28,65</sup> and demonstrating temporal, user-defined control over *in situ* stiffening (Fig. 2c). The storage modulus and the equilibrium volumetric swelling ratio of hydrogels are proportional to the density of crosslinks within the polymer network.<sup>66</sup> The equilibrium volumetric swelling ratio of the soft hybrid-hydrogels was measured to be approximately twice that of the stiffened hybrid-hydrogels, indicating that crosslinking density increased following the stiffening reaction (Fig. S5, ESI†).

Likewise, scanning electron micrographs showed a loosely organized morphology within the soft hybrid-hydrogels that became more highly interconnected upon stiffening (Fig. 2d). The initial thiol-Michael addition polymerization preceded a step-growth mechanism where one thiol reacted with one  $\alpha$ MA. This mechanism produced a homogeneous distribution of PEG $\alpha$ MA and clickable dECM throughout hybrid-hydrogels as visualized by confocal microscopy (Fig. 2e).


### 3.2. Hydrolytic stability

Synthetic PEG-based hydrogels have been widely employed to study the cell-matrix interactions associated with the initiation of fibrotic disease.<sup>19,37,63,67</sup> *In vitro* studies of fibroblast activation in response to modulus changes in PEG-based biomaterials have revealed that this differentiation is reversible when high modulus hydrogels ( $> 15$  kPa) are softened ( $< 7$  kPa).<sup>19–21</sup> Hydrolysis in these traditional Michael-addition, thiol-ene biomaterials occurs preferentially at ester linkages between the polymer backbone (*e.g.*, PEG) and the acrylate or methacrylate (MA) functional end groups that facilitate polymerization,<sup>68</sup> and this leads to the breakdown of the crosslinking within step or chain growth networks (Fig. 3a). The presence of an ester bond between the PEG macromers and functional groups in many of these materials has resulted in irreversible hydrolytic cleavage that degrades hydrogel samples completely within 21 days.<sup>69</sup> This hydrolysis limits our ability to model chronic diseases, such as fibrosis, that develop over long time periods. Therefore, the hybrid-hydrogel system presented here was designed to withstand hydrolysis over the long culture periods required to emulate chronic disease by



**Fig. 3** (A) Hydrolysis in traditional PEGMA biomaterials occurred preferentially at ester linkages between PEG and the MA functional end groups leading to cleavage of the polymer network and a decrease in elastic modulus. (B) The hybrid-hydrogel system was designed to withstand hydrolysis by conjugating the MA to the PEG backbone on the opposite side of the carbonyl as a typical MA group. This  $\alpha$ MA functional group allowed hydrolysis to occur by releasing an ethanol molecule and not degrading the crosslinked polymer network. (C) Linear regression analysis of the elastic modulus for stiffened PEG $\alpha$ MA hybrid-hydrogels and PEGMA synthetic hydrogels showed that the elastic modulus of the hybrid-hydrogel did not significantly decrease over 60 days ( $m = 0.009$ ,  $p = 0.81$ ), while the elastic modulus of the PEGMA hydrogels significantly decreased ( $m = -0.265$ ,  $p < 0.0001$ ). PEGMA hydrogel modulus values fell below the range considered pathological ( $>10$  kPa) by Day 20 ( $n = 4$ , shaded areas represent 95% confidence intervals). (D) Linear regression analysis of stiffened PEG $\alpha$ MA hybrid and PEGMA synthetic hydrogels dry mass measurements over 60 days revealed that the PEGMA hydrogels may be losing mass at a faster rate than the hybrid-hydrogels ( $m = -0.576$ ,  $p = 0.086$  versus  $m = -0.399$ ,  $p = 0.421$ , respectively), however these trends are not statistically significant.

conjugating the MA to the PEG backbone on the opposite side of the carbonyl as a typical MA group. This unique placement of the ester allowed hydrolysis to occur without affecting the crosslinked polymer network (Fig. 3b).<sup>48</sup> Additionally, the presence of the carbonyl group imparted high reactivity during chain-growth homopolymerization that is lacking for typical vinyl monomers. Hydrolytic stability of stiffened PEG $\alpha$ MA hybrid-hydrogels was monitored by measuring bulk mechanical properties and mass loss over 60 days in culture. These results were compared to stiffened, fully synthetic PEGMA. The elastic modulus of stiffened PEG $\alpha$ MA hybrid-hydrogels remained stable over 60 days, with a slope that was not significantly different from zero ( $m = 0.009$ ,  $p < 0.05$ , linear regression) (Fig. 3c). The stiffened PEGMA hydrogel, however, began to degrade after just 10 days in PBS,



**Fig. 4** (A) Metabolic activity results from days 3, 5, 7, and 9 were normalized to initial readings at day 1 and indicated that both soft and stiff hybrid-hydrogel substrates supported a significantly increased levels of cellular viability through day 9. ( $N = 6$ , mean  $\pm$  SEM,  $*p < 0.05$ , ANOVA, Tukey Test). (B) Representative images of cells stained for Calcein-AM (green) and Hoechst (blue). Cells positive for green and blue were considered live, while cells stained for blue only were considered dead. Scale bars, 25  $\mu$ m.

and the elastic modulus of this material decreased below a level recapitulating fibrotic tissue between day 10 and 20, and decreased linearly over the course of 60 days ( $m = -0.265$ ,  $p < 0.0001$ ) (Fig. 3a). PEGMA hydrogel mass also decreased at a faster rate ( $m = -0.576$ ,  $p = 0.086$ , linear regression) than the stiffened PEG $\alpha$ MA hybrid-hydrogels ( $m = -0.399$ ,  $p = 0.421$ , linear regression), although these trends are not statistically significant (Fig. 3d).

### 3.3. Cell viability


To confirm that this new hybrid-hydrogel system was cyto-compatible, wildtype PDGFR $\alpha$  fibroblasts were seeded onto

soft or stiff samples and metabolic activity was measured over time using a resazurin-based PrestoBlue™ Cell Viability assay. Metabolic activity significantly increased over nine days on both soft and stiff hybrid-hydrogels compared to day 1 (Fig. 4a). This increase in metabolic activity can be attributed to cellular proliferation over time. Representative images of cells stained for Calcein-AM (green) and Hoechst (blue) confirmed fibroblast viability on soft and stiff hybrid-hydrogels on days 1 and 7. All cells cultured on soft hybrid-hydrogels were collected for analysis on day 7, while soft hybrid-hydrogels that were stiffened on day 7 were collected for viability analysis on day 9. Results confirmed fibroblast viability through the dynamic stiffening process. Cells positive for green and blue were considered live, while cells stained for blue only were considered dead (Fig. 4b).

### 3.4. Cell activation

It is well established that both composition and mechanical properties of ECM are significantly altered during the progression of fibrosis and that these alterations influence cellular function.<sup>11,12,33,70</sup> Deciphering whether composition or mechanical properties are the major drivers of disease has remained challenging due to a limited number of experimental techniques that allow for precise spatiotemporal control over these parameters. Booth *et al.* cultured primary human lung fibroblasts on acellular normal and fibrotic human lung slices

that had significantly different moduli ( $1.6 \pm 0.08$  kPa and  $7.3 \pm 0.6$  kPa, respectively) and observed a significant increase in the production of  $\alpha$ SMA in the cells seeded on the fibrotic sections compared to cells on normal lung slices.<sup>33</sup> While the use of acellular normal and fibrotic human lung mimics the *in vivo* scenario, this system is not readily amenable for studying the relative contribution of ECM composition and stiffness. Recently, to overcome this limitation, polyacrylamide hydrogels of distinct moduli were functionalized with solubilized dECM from control and fibrotic human lungs to decouple mechanical properties from substrate stiffness. This study found that substrate stiffness was the dominant factor initiating activation of fibroblasts, and pericytes cultured on medium ( $4.4 \pm 0.5$  kPa) and high ( $23.7 \pm 2.3$  kPa) modulus substrates replicated transitioning and fibrotic human lung, respectively.<sup>30</sup> These cells expressed significantly increased levels of  $\alpha$ SMA when compared to cells cultured on soft hydrogels ( $1.8 \pm 0.5$  kPa) replicating healthy lung tissue.<sup>30</sup> These results demonstrated that changes in  $\alpha$ SMA expression and organization were mechano-sensitive regardless of composition. However, this culture system does not allow for temporally changing mechanical properties over time. These systems enabled researchers to elucidate certain aspects regarding the influence of lung composition and stiffness on fibroblast activation in a static microenvironment, but the remaining limitation was that these systems could not be altered over time to recapitulate disease.



**Fig. 5** (A) Schematic depicting the timeline for temporal stiffening during activation experiments. Gray and dark blue bars indicated the culturing time of dual-reporter fibroblasts on soft and stiff substrates, respectively. Cells were cultured in 1% FBS media for all conditions. The photoinitiator (LAP) was added to culture media on day 6 for hydrogels to be stiffened, and 365 nm UV light at  $10 \text{ mW cm}^{-2}$  ( $h\nu$ ) was applied for 5 min at day 7. Pink lines represent when samples were collected and analyzed. (B) Average proportion of dual-reporter fibroblasts that positively expressed Col1a1-GFP (green) and  $\alpha$ SMA-RFP (red) for soft, stiff and stiffened conditions ( $n = 6$ , mean  $\pm$  SEM). Significantly more cells cultured on stiff and stiffened substrates expressed Col1a1-GFP and  $\alpha$ SMA-RFP than those cultured on soft substrates. (ANOVA, Tukey Test,  $**p < 0.0001$ ). (C) Representative images of dual-reporter fibroblasts on soft and stiff hybrid-hydrogels on day 7 and stiffened hybrid hydrogels on day 9 showed expression of Col1a1-GFP and  $\alpha$ SMA-RFP. Dual-reporter fibroblasts also demonstrated increased spreading and more spindle-like morphology on the stiff and stiffened hybrid-hydrogels compared to fibroblasts cultured on soft hybrid-hydrogels. Scale bars, 25  $\mu\text{m}$ .

The hybrid-hydrogel system engineered and presented in the current article offers an *in vitro* system to allow delineation of the contributions of composition *versus* mechanical environment during disease initiation and progression *in vitro*. The ability of the hybrid-hydrogel system to provide temporal control over substrate modulus in the presence of cells permits the evaluation of the effect of dynamic modulus variation on primary murine PDGFR $\alpha$ + dual-reporter fibroblasts. Here, we used PDGFR $\alpha$ + dual-reporter fibroblasts to allow real-time analysis of fibroblast activation (*i.e.*, col1a1 and  $\alpha$ SMA transgene expression). PDGFR $\alpha$ + dual-reporter fibroblasts were seeded onto soft hybrid-hydrogels, photoinitiator (LAP) was added to culture media on day 6, and 365 nm UV light at 10 mW cm $^{-2}$  ( $h\nu$ ) was applied for 5 min at day 7 to stiffen these substrates. Fibroblast activation on these stiffened samples was compared to cells cultured on soft or stiff hybrid-hydrogel controls (Fig. 5a). There was a significant increase in the expression of myofibroblast transgenes Col1a1 and  $\alpha$ SMA, respectively, when PDGFR $\alpha$ + dual-reporter fibroblasts were cultured on stiff (87.2%, 90.3%) and dynamically stiffened hydrogels (88.6%, 88.9%) compared to soft hydrogels (36.7%, 37.2%) (Fig. 5b,  $p < 0.0001$ , ANOVA, Tukey Test). The higher levels of myofibroblast transgene expression on the stiffened hydrogels were comparable to those measured in cells cultured only on stiff hydrogels, and demonstrates that the fibroblasts were activated in response to *in situ* stiffening. Representative images also showed a morphological difference between PDGFR $\alpha$ + dual-reporter fibroblasts cultured on the soft substrates (small and rounded) and those grown on the stiff and stiffened substrates (larger and more spread out; Fig. 5c). This change in cellular morphology and the presence of  $\alpha$ SMA stress fibers are hallmarks of the myofibroblast phenotype that have been attributed to increases in substrate moduli.<sup>19,21,37,71</sup> Similar responses were observed in primary dual-reporter fibroblasts cultured on fully synthetic PEG $\alpha$ MA hydrogel controls in response to the *in situ* stiffening (Fig. S6, ESI $^\dagger$ ).

Spatial heterogeneity is another hallmark of fibrotic disease that is important to replicate *in vitro*. Gradient stiffness polyacrylamide hydrogel substrates with modulus values ranging from 0.1 to 50 kPa that mimicked the increasing stiffness of crosslinked fibrotic lesions observed in murine bleomycin models showed notable transitions in fibroblast morphology compared to spindle-shaped cells typical of activated myofibroblasts observed *in vivo* at higher stiffness levels.<sup>16</sup> Additionally, human lung fibroblasts seeded onto these materials expressed gradual increases in procollagen I and  $\alpha$ SMA along the stiffness gradient, indicating that the matrix stiffness progressively activated fibroblasts. Another group investigated the influence of pattern size on hepatic stellate cells using UV-induced secondary crosslinking restricted with a photomask to spatially control mechanical properties with a modulus range of  $2.5 \pm 0.6$  kPa outside the patterns to  $15.3 \pm 5.7$  kPa within the patterns.<sup>16</sup> There was an expression of high levels of  $\alpha$ SMA and type I collagen on stiffer substrates, and the cells responded based on the local stiffness within the patterns. However, they remained quiescent on stiff substrates if the feature size was not sufficient to allow cell spreading.<sup>34</sup>




Fig. 6 (A) A chrome on quartz photomask with two line patterns of either 50- or 100-micron width and spacing was placed in close contact with the hybrid hydrogel surfaces, which were exposed to 365 nm, 10 mW cm $^{-2}$  at for 5 min, to spatially pattern defined regions of increased elastic modulus. (B) Representative images of PDGFR $\alpha$ + dual reporter cells on both patterns. (C) Cells expressed significantly higher levels of col1a1 on both sizes within the stiff regions when compared to cells within the soft regions. There was an emerging trend of a bigger difference of expression with the larger spacing. This data is evidence of ability to spatially activate cells on the hybrid-hydrogel system.

To investigate the influence of the spatial distribution of increases in matrix stiffness on PDGFR $\alpha$ + dual-reporter fibroblasts over 7 days, patterned hybrid-hydrogels were fabricated by exposing soft substrates to light through a chrome-on-quartz photomask comprised of either 50- or 100-micron wide lines (Fig. 6a). Fibroblasts expressed significantly higher levels of the col1a1 transgene on both patterns within the stiff regions compared to the soft regions (Fig. 6b). Trends towards greater differences in expression were observed for both transgenes between the soft and stiff regions on the 100 micron pattern, demonstrating that tuning spatial patterning might impact the degree of cellular activation (Fig. 6c). Collectively, these studies have revealed that the phenotype of PDGFR $\alpha$ + dual-reporter

fibroblasts is highly dependent on substrate mechanical properties, and spatiotemporally stiffening can recreate the heterogeneous mechanical cues that cells encounter *in vivo* during fibrotic disease progression.

## 4. Conclusion

Here, a hydrolytically stable hybrid-hydrogel stiffening system with clickable dECM and a phototunable PEG backbone was synthesized and characterized. These hybrid-hydrogels integrated complex biologically relevant compositions into biomaterials that facilitated spatiotemporal control over mechanical properties to generate a platform for studying the dynamic molecular and cellular mechanisms underlying fibrosis. The dual-stage polymerization mechanism provided control over initial elastic modulus and supported spatiotemporal control over precise increases in local mechanical properties *in situ*, recreating the heterogeneous ECM stiffening that cells encounter *in vivo*. Using pulmonary fibrosis as a model of chronic fibrotic disease, we employed this *in vitro* system to investigate the response of PDGFR $\alpha$ + fibroblasts from dual-transgenic reporter mice to local matrix stiffening. Experimental results indicated that fibroblasts cultured on stiff and temporally stiffened substrates with moduli replicating diseased tissue exhibited increased activation through the measurement of Col1a1 and  $\alpha$ SMA transgene expression compared to those grown on soft substrates replicating healthy tissue. A phenotypic transition from quiescent to activated fibroblasts was initiated by exploiting a sequential crosslinking reaction scheme in these novel hybrid-hydrogels. In the present article, clickable dECM provided the complex compositional properties of healthy lung ECM. However, future experiments could include clickable dECM derived from fibrotic dECM to enable the decoupling of fibrotic tissue composition from mechanics for fundamental studies to probe how fibroblasts interact with and receive information from the extracellular microenvironment. This versatile system could also enable the encapsulation of healthy or fibrotic PDGFR $\alpha$ + fibroblasts within 3D hybrid-hydrogels to investigate cellular responses to dynamic biophysical changes in the extracellular environment in a more physiologically relevant way. Harnessing independent and dynamic control over the presentation of biochemical and biophysical cues to cells cultured within 3D hybrid-hydrogels could allow future experiments with more control over experimental parameters that will improve our ability to study the cellular and molecular mechanisms underlying fibrotic disease initiation and progression.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgements

The authors thank Carol Mirita and Radu Moldovan, PhD from the Advanced Light Microscopy Core Facility at the University of

Colorado Anschutz Medical Campus for assistance obtaining confocal images. The authors are also grateful to Dillon Jarrell, University of Colorado, Anschutz Medical Campus for assisting with photomask design as well as Cary Kuliasha, PhD and the Nanoscale Research Facility at the University of Florida for photomask fabrication. This work was supported by funding from the National Science Foundation Division of Materials Research (NSF CAREER 1941401 to CMM), the National Institutes of Health (NHLBI P01 HL14985 to KRS), and the Department of Defense (PR 192068 to CMM and PR 181125 to KRS). The Knut and Alice Wallenberg foundation is acknowledged for generous support (DEW). This project has received funding from a European Research Council (ERC) Starting Grant under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 805361) to DEW. ST is supported by a RESPIRE3 Postdoctoral Fellowship supported by the European Respiratory Society and the European Union's H2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement (Grant No. 713406). The authors also thank the Lund University Bioimaging Center (LBIC) for providing infrastructure support for SEM measurements.

## References

- 1 M. E. Smithmyer, L. A. Sawicki and A. M. Kloxin, *Biomater. Sci.*, 2014, **2**, 634–650.
- 2 A. Desmouliere, I. A. Darby and G. Gabbiani, *Lab. Invest.*, 2003, **83**, 1689–1707.
- 3 S. Meran and R. Steadman, *Int. J. Exp. Pathol.*, 2011, **92**, 158–167.
- 4 J. H. W. Distler, A.-H. Györfi, M. Ramanujam, M. L. Whitfield, M. Königshoff and R. Lafyatis, *Nat. Rev. Rheumatol.*, 2019, **15**, 705–730.
- 5 M. Selman and A. Pardo, *Respir. Res.*, 2002, **3**, 3.
- 6 M. Selman and A. Pardo, *Proc. Am. Thorac. Soc.*, 2006, **3**, 364–372.
- 7 M. Korfei, S. Schmitt, C. Ruppert, I. Henneke, P. Markart, B. Loeh, P. Mahavadi, M. Wygrecka, W. Klepetko, L. Fink, P. Bonniaud, K. T. Preissner, G. Lochnit, L. Schaefer, W. Seeger and A. Guenther, *J. Proteome Res.*, 2011, **10**, 2185–2205.
- 8 M. G. Jones, A. Fabre, P. Schneider, F. Cinetto, G. Sgalla, M. Mavrogordato, S. Jogai, A. Alzetani, B. G. Marshall, K. M. A. O'Reilly, J. A. Warner, P. M. Lackie, D. E. Davies, D. M. Hansell, A. G. Nicholson, I. Sinclair, K. K. Brown and L. Richeldi, *JCI Insight*, 2016, **1**, e86375.
- 9 T. A. Wynn and T. R. Ramalingam, *Nat. Med.*, 2012, **18**, 1028–1040.
- 10 T. N. Wight and S. Potter-Perigo, *Am. J. Physiol.: Gastrointest. Liver Physiol.*, 2011, **301**, G950–G955.
- 11 M. W. Parker, D. Rossi, M. Peterson, K. Smith, K. Sikström, E. S. White, J. E. Connett, C. A. Henke, O. Larsson and P. B. Bitterman, *J. Clin. Invest.*, 2014, **124**, 1622–1635.
- 12 J. K. Burgess, T. Mauad, G. Tjin, J. C. Karlsson and G. Westergren-Thorsson, *J. Pathol.*, 2016, **240**, 397–409.

- 13 Y. Zhou, J. C. Horowitz, A. Naba, N. Ambalavanan, K. Atabai, J. Balestrini, P. B. Bitterman, R. A. Corley, B. S. Ding, A. J. Engler, K. C. Hansen, J. S. Hagood, F. Kheradmand, Q. S. Lin, E. Neptune, L. Niklason, L. A. Ortiz, W. C. Parks, D. J. Tschumperlin, E. S. White, H. A. Chapman and V. J. Thannickal, *Matrix Biol.*, 2018, **73**, 77–104.
- 14 J. Herrera, C. A. Henke and P. B. Bitterman, *J. Clin. Invest.*, 2018, **128**, 45–53.
- 15 A. J. Haak, Q. Tan and D. J. Tschumperlin, *Matrix Biol.*, 2018, **73**, 64–76.
- 16 F. Liu, J. D. Mih, B. S. Shea, A. T. Kho, A. S. Sharif, A. M. Tager and D. J. Tschumperlin, *J. Cell Biol.*, 2010, **190**, 693–706.
- 17 Z. Borok, J. A. Whitsett, P. B. Bitterman, V. J. Thannickal, D. N. Kotton, S. D. Reynolds, M. A. Krasnow, D. W. Bianchi, E. E. Morrissey, B. L. Hogan, J. M. Kurie, D. C. Walker, D. C. Radisky, S. L. Nishimura, S. M. Violette, P. W. Noble, S. D. Shapiro, C. J. Blaisdell and H. A. Chapman, *Proc. Am. Thorac. Soc.*, 2011, **8**, 215–222.
- 18 S. H. Phan, *Proc. Am. Thorac. Soc.*, 2008, **5**, 334–337.
- 19 K. M. Mabry, S. Z. Payne and K. S. Anseth, *Biomaterials*, 2016, **74**, 31–41.
- 20 H. Wang, L. A. Leinwand and K. S. Anseth, *Nat. Rev. Cardiol.*, 2014, **11**, 715.
- 21 A. M. Kloxin, J. A. Benton and K. S. Anseth, *Biomaterials*, 2010, **31**, 1–8.
- 22 D. M. Habiak and C. Hogaboam, *Front. Pharmacol.*, 2014, **5**, 2.
- 23 C.-J. Hu, H. Zhang, A. Laux, S. S. Pullamsetti and K. R. Stenmark, *J. Physiol.*, 2019, **597**, 1103–1119.
- 24 L. T. Saldin, M. C. Cramer, S. S. Velankar, L. J. White and S. F. Badylak, *Acta Biomater.*, 2017, **49**, 1–15.
- 25 B. M. Young, K. Shankar, C. K. Tho, A. R. Pellegrino and R. L. Heise, *Acta Biomater.*, 2019, **100**, 223–234.
- 26 R. A. Pouliot, P. A. Link, N. S. Mikhael, M. B. Schneck, M. S. Valentine, F. J. Kamga Gninzeko, J. A. Herbert, M. Sakagami and R. L. Heise, *J. Biomed. Mater. Res., Part A*, 2016, **104**, 1922–1935.
- 27 M. M. De Santis, D. A. Bölükbas, S. Lindstedt and D. E. Wagner, *Eur. Respir. J.*, 2018, **52**, 1601355.
- 28 F. Liu and D. J. Tschumperlin, *J. Visualized Exp.*, 2011, 2911, DOI: 10.3791/2911.
- 29 R. H. J. de Hilster, P. K. Sharma, M. R. Jonker, E. S. White, E. A. Gercama, M. Roobeek, W. Timens, M. C. Harmsen, M. N. Hylkema and J. K. Burgess, *Am. J. Physiol.: Lung Cell. Mol. Physiol.*, 2020, **318**, L698–L704.
- 30 P. Sava, A. Ramanathan, A. Dobronyi, X. Peng, H. Sun, A. Ledesma-Mendoza, E. L. Herzog and A. L. Gonzalez, *JCI Insight*, 2017, **2**(24), 96352.
- 31 J. Visser, P. A. Levett, N. C. te Moller, J. Besems, K. W. Boere, M. H. van Rijen, J. C. de Grauw, W. J. Dhert, P. R. van Weeren and J. Malda, *Tissue Eng., Part A*, 2015, **21**, 1195–1206.
- 32 A. Marinković, F. Liu and D. J. Tschumperlin, *Am. J. Respir. Cell Mol. Biol.*, 2013, **48**, 422–430.
- 33 A. J. Booth, R. Hadley, A. M. Cornett, A. A. Dreffs, S. A. Matthes, J. L. Tsui, K. Weiss, J. C. Horowitz, V. F. Fiore, T. H. Barker, B. B. Moore, F. J. Martinez, L. E. Niklason and E. S. White, *Am. J. Respir. Crit. Care Med.*, 2012, **186**, 866–876.
- 34 M. Guvendiren and J. A. Burdick, *Nat. Commun.*, 2012, **3**, 792.
- 35 A. M. Rosales, C. B. Rodell, M. H. Chen, M. G. Morrow, K. S. Anseth and J. A. Burdick, *Bioconjugate Chem.*, 2018, **29**, 905–913.
- 36 A. M. Rosales, S. L. Vega, F. W. DelRio, J. A. Burdick and K. S. Anseth, *Angew. Chem., Int. Ed.*, 2017, **56**, 12132–12136.
- 37 K. M. Mabry, R. L. Lawrence and K. S. Anseth, *Biomaterials*, 2015, **49**, 47–56.
- 38 C. M. Magin, D. L. Alge and K. S. Anseth, *Biomed. Mater.*, 2016, **11**, 022001.
- 39 E. R. Ruskowitz and C. A. DeForest, *Nat. Rev. Mater.*, 2018, **3**, 17087.
- 40 J. A. Zepp, W. J. Zacharias, D. B. Frank, C. A. Cavanaugh, S. Zhou, M. P. Morley and E. E. Morrissey, *Cell*, 2017, **170**, 1134–1148.e1110.
- 41 S. T. Magness, R. Bataller, L. Yang and D. A. Brenner, *Hepatology*, 2004, **40**, 1151–1159.
- 42 P. A. Reyfman, J. M. Walter, N. Joshi, K. R. Anekalla, A. C. McQuattie-Pimentel, S. Chiu, R. Fernandez, M. Akbarpour, C.-I. Chen, Z. Ren, R. Verma, H. Abdala-Valencia, K. Nam, M. Chi, S. Han, F. J. Gonzalez-Gonzalez, S. Soberanes, S. Watanabe, K. J. N. Williams, A. S. Flozak, T. T. Nicholson, V. K. Morgan, D. R. Winter, M. Hinchcliff, C. L. Hrusch, R. D. Guzy, C. A. Bonham, A. I. Sperling, R. Bag, R. B. Hamanaka, G. M. Mutlu, A. V. Yeldandi, S. A. Marshall, A. Shilatifard, L. A. N. Amaral, H. Perlman, J. I. Sznajder, A. C. Argento, C. T. Gillespie, J. Dematte, M. Jain, B. D. Singer, K. M. Ridge, A. P. Lam, A. Bharat, S. M. Bhorade, C. J. Gottardi, G. R. S. Budinger and A. V. Misharin, *Am. J. Respir. Crit. Care Med.*, 2018, **199**, 1517–1536.
- 43 R. C. Chambers and P. F. Mercer, *Ann. Am. Thorac. Soc.*, 2015, **12**, S16–S20.
- 44 A. Camelo, R. Dunmore, M. A. Sleeman and D. L. Clarke, *Front. Pharmacol.*, 2013, **4**, 173.
- 45 F. Liu, D. Lagares, K. M. Choi, L. Stopfer, A. Marinković, V. Vrbanac, C. K. Probst, S. E. Hiemer, T. H. Sisson, J. C. Horowitz, I. O. Rosas, L. E. Fredenburgh, C. Feghali-Bostwick, X. Varelas, A. M. Tager and D. J. Tschumperlin, *Am. J. Physiol.: Lung Cell. Mol. Physiol.*, 2014, **308**, L344–L357.
- 46 B. D. Fairbanks, M. P. Schwartz, C. N. Bowman and K. S. Anseth, *Biomaterials*, 2009, **30**, 6702–6707.
- 47 D. Davis-Hall, V. Nguyen, T. J. D'Ovidio, E. Tsai, G. Bilousova and C. M. Magin, *Adv. Biosyst.*, 2019, **3**, 1900022.
- 48 X. Tong, J. Lai, B.-H. Guo and Y. Huang, *J. Polym. Sci., Part A: Polym. Chem.*, 2011, **49**, 1513–1516.
- 49 M. S. Hahn, L. J. Taite, J. J. Moon, M. C. Rowland, K. A. Ruffino and J. L. West, *Biomaterials*, 2006, **27**, 2519–2524.
- 50 S. Lin-Gibson, S. Bencherif, J. A. Cooper, S. J. Wetzel, J. M. Antonucci, B. M. Vogel, F. Horkay and N. R. Washburn, *Biomacromolecules*, 2004, **5**, 1280–1287.
- 51 D. E. Wagner, N. R. Bonenfant, D. Sokocevic, M. J. DeSarno, Z. D. Borg, C. S. Parsons, E. M. Brooks, J. J. Platz,

- Z. I. Khalpey, D. M. Hoganson, B. Deng, Y. W. Lam, R. A. Oldinski, T. Ashikaga and D. J. Weiss, *Biomaterials*, 2014, **35**, 2664–2679.
- 52 F. E. Uhl, D. E. Wagner and D. J. Weiss, *Methods Mol. Biol.*, 2017, **1627**, 253–283.
- 53 J. C. Grim, I. A. Marozas and K. S. Anseth, *J. Controlled Release*, 2015, **219**, 95–106.
- 54 K. R. Chirco, K. S. Worthington, M. J. Flamme-Wiese, M. J. Riker, J. D. Andrade, B. M. Ueberheide, E. M. Stone, B. A. Tucker and R. F. Mullins, *Acta Biomater.*, 2017, **57**, 293–303.
- 55 C. M. Kirschner and K. S. Anseth, *Small*, 2013, **9**, 578–584.
- 56 T. K. L. Meyvis, S. C. De Smedt, J. Demeester and W. E. Hennink, *J. Rheol.*, 1999, **43**, 933–950.
- 57 I. f. L. A. Research, *Journal*, 2011.
- 58 J. Green, M. Endale, H. Auer and A.-K. T. Perl, *Am. J. Respir. Cell Mol. Biol.*, 2016, **54**, 532–545.
- 59 P. E. Farahani, S. M. Adelmund, J. A. Shadish and C. A. DeForest, *J. Mater. Chem. B*, 2017, **5**, 4435–4442.
- 60 H. Ma, A. R. Killaars, F. W. DelRio, C. Yang and K. S. Anseth, *Biomaterials*, 2017, **131**, 131–144.
- 61 M. Gajendiran, J.-S. Rhee and K. Kim, *Tissue Eng., Part B*, 2017, **24**, 66–74.
- 62 S. T. Gould, N. J. Darling and K. S. Anseth, *Acta Biomater.*, 2012, **8**, 3201–3209.
- 63 C. M. Kirschner, D. L. Alge, S. T. Gould and K. S. Anseth, *Adv. Healthcare Mater.*, 2014, **3**, 649–657.
- 64 K. E. Bailey, C. Pino, M. L. Lennon, A. Lyons, J. G. Jacot, S. R. Lammers, M. Konigshoff and C. M. Magin, *Am. J. Respir. Cell Mol. Biol.*, 2020, **62**, 14–22.
- 65 F. Liu, C. M. Haeger, P. B. Dieffenbach, D. Sicard, I. Chrobak, A. M. F. Coronata, M. M. S. Velandia, S. Vitali, R. A. Colas, P. C. Norris, A. Marinković, X. Liu, J. Ma, C. D. Rose, S.-J. Lee, S. A. A. Comhair, S. C. Erzurum, J. D. McDonald, C. N. Serhan, S. R. Walsh, D. J. Tschumperlin and L. E. Fredenburgh, *JCI Insight*, 2016, **1**(8), e86987.
- 66 C. M. Kirschner and K. S. Anseth, *Acta Mater.*, 2013, **61**, 931–944.
- 67 H. Wang, S. M. Haeger, A. M. Kloxin, L. A. Leinwand and K. S. Anseth, *PLoS One*, 2012, **7**, e39969.
- 68 A. Metters and J. Hubbell, *Biomacromolecules*, 2004, **6**, 290–301.
- 69 H. Shih and C. C. Lin, *Biomacromolecules*, 2012, **13**, 2003–2012.
- 70 H. B. Schiller, I. E. Fernandez, G. Burgstaller, C. Schaab, R. A. Scheltema, T. Schwarzmayr, T. M. Strom, O. Eickelberg and M. Mann, *Mol. Syst. Biol.*, 2015, **11**, 819.
- 71 S. R. Caliari, M. Perepelyuk, B. D. Cosgrove, S. J. Tsai, G. Y. Lee, R. L. Mauck, R. G. Wells and J. A. Burdick, *Sci. Rep.*, 2016, **6**, 21387.